Project Name: Amphotercin B.
Vancouver company, iCo Therapeutics Inc., has partnered with UBC to advance Dr. Kishor Wasan’s new formulation of Amphotericin B for the treatment of leishmaniasis and other fungal infections. In developed countries, fungal infections are a leading contributor to death among immunocompromised individuals (e.g. cancer and AIDS patients). In the developing world, leishmaniasis is contracted by 2 million people a year. Dr. Wasan’s formulation, being developed to be taken orally without serious side-effects, will be a significant improvement on the current treatment which is expensive, can only be administered by injection and is highly toxic. This makes the technology ideal for application in the developing world, and our commercialization agreement with iCo ensures that development of the formulation will embrace our global access objectives.
Since entering into this partnership iCo announced positive preclinical data relating to the oral amphotericin formulation licensed from UBC. Significant antifungal activity was seen at dosage levels where no kidney toxicity was observed, and the formulation displayed a dramatic knock-down of a parasitic infection that causes Visceral Leishmaniasis (VL), with greater than 99% eradication of parasitic infection at the tested dosages. In April 2009, iCo and the Canadian Institutes of Health Research (CIHR) established the Research Chair in Drug Delivery for Neglected Global Diseases held by Dr. Kishor Wasan. I September 2009, iCo entered a partnership with Gates Foundation funding recipients, The Consortium for Parasitic Drug Development, with initial funding targeted at formulation optimization for tropical conditions.
Relevant NGDI Articles
A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. Gershkovich P, Ibrahim F, Sivak O, Darlington JW, Wasan KM. Drug Dev Ind Pharm. 2014 Mar;40(3):338-44. Epub 2013 Feb 4.
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Kagan L, Gershkovich P, Wasan KM, Mager DE. Pharm Res. 2014 Jan;31(1):35-45.
Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis. Ibrahim F, Sivak O, Wasan EK, Bartlett K, Wasan KM. Lipids Health Dis. 2013 Oct 29;12:158.
Impact of co-administration of protonated nanostructured aluminum silicate (cholesterol absorption inhibitor) on the absorption of lipid soluble vitamins D3 and K1: an assessment of pharmacokinetic and in vitro intraluminal processing. Ibrahim F, Sivak O, Wong C, Hopkins P, Midha A, Gordon J, Darlington JW, Wasan KM. Eur J Pharm Sci. 2013 May 13;49(2):125-32.
Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats. Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Wasan KM. Drug Dev Ind Pharm. 2013 Sep;39(9):1277-83.
Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects. Gregory-Evans CY, Wang X, Wasan KM, Zhao J, Metcalfe AL, Gregory-Evans K. J Clin Invest. 2014 Jan 2;124(1):111-6. Epub 2013 Dec 20.
Review of the quality of pediatric medications in developing countries. Conway J, Bero L, Ondari C, Wasan KM. J Pharm Sci. 2013 May;102(5):1419-33. Review.
Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Wasan KM. Eur J Pharm Sci 2012 46(5):323-8.
Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bartlett K, Wasan KM. Int J Pharm 2012 436(1-2):318-323.
Neglected populations: Safeguarding the health of street-involved children in Ghana. Osei-Twum JA and Wasan KM. J Pharm Sci 2012 101(10):3619-3622.
Impact of the trade‐related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. Babovic S and Wasan KM. Journal of Pharmaceutical Sciences. 2011, Vol100:3:816-821.
Increasing access to essential medicines: Diversifying Canada’s approach. Brown S, Babovic S, Wasan KM. Journal of Pharmaceutical Sciences. 2011, Vol100:2:411-415.
In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines. Leon CG, Lee J, Bartlett K, Gershkovic P, Wasan EK, Zhao J, Clement JG, and Wasan KM. Lipids in Health and Disease. 2011, Vol10:1:144
Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. Kagan L, Gershkovic P, Wasan KM, and Mager DE. The AAPS Journal. 2011, Vol13:2:255-264.
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Sivak O, Gershkovich P, Lin M, Wasan EK, Zhao J, Owen D, Clement JG, and Wasan KM. Lipids in Health and Disease. 2011, Vol10:1:135.
Impact of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement on India as a Supplier of Generic Antiretrovirals. Bobovic S, Wasan K. Journal of Pharmaceutical Sciences 2010. published online doi:10.1002/jps.22326.
Increasing Access to Essential Medicines: Diversifying Canada’s Approach. Brown S, Bobovich S, and Wasan K. Journal of Pharmaceutical Sciences, 2010. Vol X p 1-5. doi: 10.1002/jps.22300.
Which New Approaches to Tackling Neglected Tropical Diseases Show Promise? Spiegel JM, Dharamsi S, Wasan KM, Yassi A, Singer B, et al. PLoS Med 2010. 7(5): e1000255.